CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM IF PUBLICLY DISCLOSED. [***] INDICATES THAT INFORMATION HAS BEEN REDACTED. RESEARCH, DEVELOPMENT AND...Development and Commecialization Agreement • October 13th, 2020 • Royalty Pharma PLC • Pharmaceutical preparations • Massachusetts
Contract Type FiledOctober 13th, 2020 Company Industry JurisdictionThis Agreement is a modification and continuation of a relationship originally set forth in an earlier Cystic Fibrosis Research Alliance and Commercialization Agreement dated as of May 19, 2000 (the “Original Agreement”), between the Cystic Fibrosis Foundation, which is an Affiliate of CFFT, and Aurora Biosciences Corporation, which was acquired by Vertex in 2001. Except as specifically provided herein, this Agreement supercedes in its entirety the Original Agreement which shall be of no further force and effect.
Confidential Treatment Requested. Confidential portions of this document have been redacted and have been separately filed with the Commission AMENDMENT NO. 1 TO RESEARCH, DEVELOPMENT AND COMMECIALIZATION AGREEMENT (the "Existing Agreement") DATED MAY...Development and Commecialization Agreement • March 16th, 2006 • Vertex Pharmaceuticals Inc / Ma • Pharmaceutical preparations
Contract Type FiledMarch 16th, 2006 Company IndustryThis Amendment No. 1 (the "Amendment") is made this 6th day of January, 2006 (the "Effective Date") between Vertex, a Massachusetts corporation with principal offices at 130 Waverly Street, Cambridge, MA 02139-4242 and CFFT, a Delaware corporation with principal offices at 6931 Arlington Road, Bethesda, Maryland 20814. Vertex and CFFT are referred to hereinafter collectively as the Parties.